Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Pfizer Upgraded To Overweight; Goldman Downgrades Kimco To Sell

|Includes: Cognizant Technology Solutions Corporation (CTSH), JNJ, KIM, LABL, PFE, SAIC, T, ZBH

Here are today's top Wall Street analyst ratings where's unbiased fair value estimates support the recommendation.

Top Upgrades
  • Cantor Fitzgerald raised Cognizant Technology Solutions' (NASDAQ:CTSH) target price to $67 per share.'s fair value estimate is slightly lower at $66 per share implying 18% upside.

  • Barclays upgraded Pfizer (NYSE:PFE) from Equal Weight to Overweight. Twelve valuation models suggest the stock is currently 15% undervalued.

  • Jefferies Group reiterated its Buy rating on AT&T (NYSE:T). Eleven valuation models imply a fair value of $45.50 per share representing 15% upside.

  • Citigroup upgraded Zimmer Biomet (NYSE:ZBH). The rating change is supported by the company's underlying fundamentals.

Top Downgrades
  • Citigroup downgraded Science Applications International (NYSE:SAIC). Shares are currently trading at a 24% premium.

  • KeyCorp downgraded Multi-Color Corp (NASDAQ:LABL) from Sector Weight to Underweight. Ten free cash flow models imply the stock is 20% overvalued.

  • Barclays downgraded Johnson & Johnson (NYSE:JNJ) from Overweight to Equal Weight. Fundamentals support the rating change.

  • Goldman Sachs downgraded Kimco Realty (NYSE:KIM) from Neutral to Sell. Eight valuation models support the rating and conclude a negative 14% margin of safety.